PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : I

Records returned : 85 (on 24 Nov 2024 at 02:06:31).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Ibandronic acid
No Information Returned
Ibrutinib
No Information Returned
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Preferred
07.01.01
10.01.01
10.03.02
Ibuprofen
Osteoarthritis
Green
Formulations :
  • Gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
5% gel. This is the least costly option for primary care.
07.01.01
10.01.01
10.03.02
Ibuprofen
Dysmenorrhoea
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Reserved for patients with swallowing difficulties
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Restricted for patients where an oral NSAID is not suitable.
07.01.01
10.01.01
10.03.02
Ibuprofen
Ductus arteriosus closure
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Paediatric consultants only
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Restricted for patients where an oral NSAID is not suitable
07.01.01
10.01.01
10.03.02
Ibuprofen
Pain & inflammation - musculoskeletal
Non Formulary
Formulations :
  • Capsules
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Ibuprofen lysine
No Information Returned
Ibuprofen sodium dihydrate
No Information Returned
Ibuprofen/pseudoephedrine hydrochloride
No Information Returned
Icatibant acetate
No Information Returned
Ichthammol
No Information Returned
02.12.00
Icosapent
Lipid modification
Green
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
With statin therapy in patients with raised triglycerides
Idarubicin hydrochloride
No Information Returned
02.08.04
Idarucizumab
Anticoagulation reversal
Red
Formulations :
  • Intravenous injection (IV)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Dabigatran anticoagulant reversal. RESTRICTED to Haematologists only
11.08.02
11.08.03
Idebenone
Leber's optic neuropathy
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
NHSE Specialised Commissioned Services only
Idoxuridine in dimethyl sulfoxide
No Information Returned
Ifosfamide
No Information Returned
02.05.01
Iloprost
Raynaud's Phenomenon
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Imatinib mesilate
No Information Returned
Imidapril hydrochloride
No Information Returned
Imiglucerase
No Information Returned
05.01.02
05.01.07
Imipenem with cilastatin
Bacterial infection
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
Important
Restricted Antimicrobial - requires Microbiology Specialist Approval.
04.03.01
04.07.03
07.04.02
Imipramine hydrochloride
Pain (Neuropathic)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.03.01
04.07.03
07.04.02
Imipramine hydrochloride
Overactive bladder (adults)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Imiquimod
No Information Returned
02.12.00
Inclisiran
Lipid modification
Green
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Prescribing in secondary care is commissioned by NHSE - Blueteq forms are required.
Indacaterol maleate
No Information Returned
Indacaterol/glycopyrronium
No Information Returned
Indacaterol/mometasone
No Information Returned
02.02.01
Indapamide
Hypertension
Green
Formulations :
  • Modified release tablets
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Preferred
Preferred thiazide diuretic
05.03.01
Indinavir
HIV infection
Red
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
SA
NICE
Important
Restricted Antimicrobial - requires GUM Specialist approval
07.01.01
10.01.01
Indometacin
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Capsules
  • Capsules (slow release)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Only for use in gout. ASPH restricted to rheumatology only.
07.01.01
10.01.01
Indometacin
Ductus arteriosus closure
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Paediatric consultants only
07.04.01
Indoramin
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Uveitis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
NHSE Specialist Commissioned services only. Not routinely commissioned.
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Inflammatory bowel disease
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
For UC & CD. Prescribe by brand
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Immunotherapy related colitis
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
ICB
BlueTeq
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Connective tissue disease
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Pouchitis
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Rheumatoid arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Ankylosing spondylitis
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Graft versus Host Disease (GVHD)
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Behcet's syndrome
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Highly specialist centres only
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Inflammatory bowel disease - paediatric use
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
NHSE Commissioned - Specilaist centres only
01.05.03
10.01.03
13.05.02
13.05.03
Infliximab
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Influenza
No Information Returned
Influenza H1N1(Split viron, inactivated, adjuvanted)
No Information Returned
Influenza H1N1(Whole viron, vero, inactivated)
No Information Returned
Ingenol mebutate
No Information Returned
Inosine pranobex
No Information Returned
Inotuzumab
No Information Returned
INR blood testing reagents
No Information Returned
Ins degludec/liraglutide
No Information Returned
06.01.01
Insulin aspart
Diabetes Mellitus
Green
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Insulin degludec
No Information Returned
Insulin detemir
No Information Returned
06.01.01
Insulin glargine
Diabetes Mellitus
Green
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Insulin glargine/lixisenatide
No Information Returned
Insulin glulisine
No Information Returned
Insulin human
No Information Returned
Insulin human inhaled
No Information Returned
06.01.01
Insulin Lispro
Diabetes Mellitus
Green
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Insulin zinc suspension
No Information Returned
Insulin zinc suspension (Crystalline)
No Information Returned
Interferon alpha
No Information Returned
Interferon beta
No Information Returned
Interferon gamma
No Information Returned
Intravenous nutrition supplements
No Information Returned
Iodine
No Information Returned
Iodine compounds
No Information Returned
Iodoform
No Information Returned
Ipecacuanha
No Information Returned
Ipilimumab
No Information Returned
Ipratropium bromide
No Information Returned
02.05.05
Irbesartan
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Irbesartan with diuretic
No Information Returned
Irinotecan hydrochloride
No Information Returned
Iron and folic acid
No Information Returned
Iron carboxymaltose
No Information Returned
Iron dextran
No Information Returned
Iron sorbitol
No Information Returned
Iron sucrose
No Information Returned
Isavuconazole
No Information Returned
04.03.02
Isocarboxazid
Depression
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Initiation and stabilisation by specialist for a minimum of 6 months before transfer of prescribing to primary care.
Isometheptene mucate
No Information Returned
05.01.09
Isoniazid
Tuberculosis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Liaise with Chest Physician. Patients with multi-drug resistant TB should be treated by a specialist centre.
Isophane insulin
No Information Returned
Isopropyl alcohol
No Information Returned
02.06.01
Isosorbide dinitrate
Angina
Green
Formulations :
  • Modified release tablets
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.06.01
Isosorbide mononitrate
Angina
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
Twice daily (assymetric) dosing is recommended
02.06.01
Isosorbide mononitrate
Angina
Green (see narrative)
Formulations :
  • Modified release capsules
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Restricted to when isosorbide mononitrate standard release is not suitable. Primary Care prescribers should follow local advice on the most cost-effective brands. OptimiseRx will be used to identify current recommendations.
Isosorbide mononitrate with aspirin
No Information Returned
Isotretinoin
No Information Returned
01.06.01
Ispaghula husk
Constipation
Green
Formulations :
  • Sachets (granules)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Isradipine
No Information Returned
Itraconazole
No Information Returned
02.06.03
Ivabradine
Angina
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Restricted to cardiology. Specialist initiation and at least one month supply before transfer to primary care
02.06.03
Ivabradine
Heart failure
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Restricted to initiation by cardiology only. Transfer of prescribing to primary care only after initiation and at least the first month supply from the specialist.
Ivacaftor
No Information Returned
Ivermectin
No Information Returned
Ixazomib
No Information Returned
10.01.03
13.05.02
13.05.03
Ixekizumab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
13.05.02
13.05.03
Ixekizumab
Ankylosing spondylitis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
13.05.02
13.05.03
Ixekizumab
Non-radiographic axial spondyloarthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
13.05.02
13.05.03
Ixekizumab
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More